预约演示
更新于：2025-07-05
Tropicamide
托吡卡胺
更新于：2025-07-05
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H20N2O2 |
InChIKeyBGDKAVGWHJFAGW-UHFFFAOYSA-N |
CAS号1508-75-4 |
关联
27
项与 托吡卡胺 相关的临床试验CTRI/2025/04/085126
A clinical study to evaluate the efficacy and safety of Kakamachi (Solanum nigrum ) extract as a natural pupil dilator in comparison with conventional pharmaceutical agent- tropicacyl plus - NIL
CTRI/2024/08/072980
To evaluate changes in hemodynamic parameters in hypertensive and nomotensive patients using intracameral injection of a mix Tropicamide 0.2 percentage . Phenylnephrine 0.31 percentage . Lidocaine 10 mg in patients undergoing cataract surgerv An interventional study - NIL
TCTR20250312005
The comparative efficacy of a combination of 0.5% cyclopentolate tropicamide, and alternating instillation of 1% cyclopentolate and 1% tropicamide in Thai pediatric refraction
100 项与 托吡卡胺 相关的临床结果
登录后查看更多信息
100 项与 托吡卡胺 相关的转化医学
登录后查看更多信息
100 项与 托吡卡胺 相关的专利（医药）
登录后查看更多信息
1,323
项与 托吡卡胺 相关的文献（医药）2025-06-10JOURNAL OF CATARACT AND REFRACTIVE SURGERY
Lens Morphology in Cataract Patients with Zonula Dialysis by Anterior Segment Optical Coherence Tomography.
Article
作者: Yuan, Hao ; Li, Xuemin ; Jiang, Xiaodan ; Liu, Ziyuan
PURPOSE:
To investigate the morphologic characteristics of lens in cataract patients with zonule dialysis (ZD) before and after cycloplegia by anterior segment optical coherence tomography (AS-OCT).
SETTING:
Peking University Third Hospital, Beijing, China.
DESIGN:
Cross-sectional observational study.
METHODS:
56 eyes from 56 participants who would undergo cataract operations were included, with 29 eyes of normal controls and 27 eyes of zonule dialysis patients. Lens morphologic parameters were then evaluated by AS-OCT, including anterior chamber depth (ACD), lens thickness (LT), lens diameter, lens vault, anterior curvature radius, posterior curvature radius, decentration and tilt of lens. After participants were treated with three-time tropicamide solution, AS-OCT was repeated to acquire the post-cycloplegia results. SPSS Software 22.0 was used for statistical analysis.
RESULTS:
The comparison of basic lens morphologic parameters without cycloplegia found only anterior curvature (P=0.039) showed significant differences between normal and ZD groups. AS-OCT measured after 30-min cycloplegia treatment showed significantly increased ACD, lens diameter, posterior curvature and decreased vault in both groups, decreased lens thickness in normal group, increased anterior curvature and decreased lens decentration in ZD group (all P<0.05). The logistic regression model showed ZD group had greater alterations of ACD (P=0.014), anterior curvature (P=0.009) and decentration (P=0.031) after cycloplegia treatment when compared with the normal group.
CONCLUSIONS:
Lens in ZD patients was characterized by steeper anterior curvature, and grater alterations of ACD, anterior curvature and decentration after cycloplegia. The comparison of lens morphologic parameters before and after cycloplegia might be the potential method to evaluate the stability of zonule.
2025-05-21ACS Applied Materials & Interfaces
Reprogramming Retinal Microglia Polarization by Efferocytosis-Mimicking Nanoparticles for Ameliorating Diabetic Retinopathy
Article
作者: Zhu, Liping ; Wang, Qing ; Wu, Jingliang ; Sun, Yong ; Liu, Chaolong ; Wang, Zhiqiang ; Li, Zhipeng ; Wang, Wenyu
Diabetic retinopathy (DR), as the most common microvascular complication of diabetes, seriously threatens the vision of diabetic patients. As the resident phagocytes of the retina, microglia participate in inflammation, neovascularization, and neurodegeneration of DR. Herein, apoptotic retinal cell membrane-coated, rapamycin-loaded mesoporous Prussian blue NPs as immunomodulators for ameliorating DR by modulating microglial polarization are reported. The apoM@mPB@Ra NPs exhibited favorable stability and biocompatibility and achieved active targeted delivery due to the specific recognition between "eat me" signal expressed on apoptotic membrane and microglia. In an LPS-induced cellular inflammation model, apoM@mPB@Ra NPs effectively promoted microglial polarization toward the anti-inflammatory phenotype (M2) by scavenging intracellular reactive oxygen species (ROS) combined with affecting the mTOR signaling pathway, leading to downregulation of pro-inflammatory cytokines IL-6 and TNF-α. Meanwhile, owing to the multienzyme-like activities of mPB in nanoparticles, apoM@mPB@Ra NPs obviously alleviated cellular hypoxia, thereby decreasing the expression of VEGF. Notably, in a mouse model of DR, intravitreally injected apoM@mPB@Ra NPs significantly improved the severity of the abnormal retinal vascular network and inflammatory microenvironment of retinopathy by down-regulating the expression of HIF-1α, VEGF, and inflammatory-related cytokines. Collectively, these findings demonstrate that apoM@mPB@Ra NPs provide a promising and effective approach for the treatment of DR.
2025-05-01RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
EVALUATION OF THE EFFECTS OF DIFFERENT MYDRIATIC DROPS USED ON CHOROIDAL VASCULARITY IN HEALTHY CHILDREN
Article
作者: Kimyon, Sabit ; Chiekhismailzadeh, Yara ; Balyemez, Burçak ; Gürbostan Soysal, Gizem ; Çetinkaya, Kübra ; Mercanlı, Murat ; Seyyar, Sevim A.
Purpose::
To evaluate the effects of mydriatics drops used primarily in routine eye examinations on the choroid tissue, which has a dense vascular network in the eye.
Methods::
This prospective observational study included 90 eyes of 90 healthy children. Optical coherence tomography images were obtained for all children before dilation. They were randomly divided into two groups (46/44). The tropicamide group received 0.5% tropicamide, and the phenylephrine group received 2.5% phenylephrine. After dilation, a second optical coherence tomography image was obtained for all children.
Results::
Subfoveal choroidal thickness values decreased significantly after dilation in the phenylephrine and tropicamide drop groups compared with predilation measurements (P = 0.001 for both). No significant difference was observed in the choroidal vascularity index values measured before and after dilation in either group (P = 0.059, P = 0.245).
Conclusion::
While 2.5% phenylephrine and 0.5% tropicamide caused a decrease in subfoveal choroidal thickness values after dilatation, there was no significant difference in choroidal vascularity index values. These results emphasize that when examining choroidal thickness and vascularity in individuals with chorioretinal disease, the selection of mydriatic agent should be taken into consideration, especially in choroidal thickness.
100 项与 托吡卡胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 睫状肌麻痹 | 美国 | 1960-02-23 | |
| 瞳孔散大 | 美国 | 1960-02-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
EURETINA2024 人工标引  | N/A | - | 53 | 壓構醖積構網遞餘鹹襯(蓋鑰築窪網積艱選構憲) = 觸繭廠簾憲鬱餘艱網製 夢簾餘鏇餘夢獵願遞淵 (構遞膚醖網製醖壓夢鑰 ) 更多 | 积极 | 2024-09-19 | |
临床4期 | 11 | 繭範醖獵醖鏇夢鹽遞製 = 選膚餘獵選蓋鏇糧糧鹽 壓選鏇鹹構鏇壓範廠齋 (壓構廠築觸築鹽鬱醖觸, 醖鑰窪簾憲壓鹹糧遞夢 ~ 醖壓夢鑰窪憲繭顧積廠) 更多 | - | 2023-03-07 | |||
临床3期 | - | 積衊鏇網繭顧網鬱築鏇(繭艱窪觸選餘鏇積廠積) = 憲獵齋餘餘繭壓齋鹹築 膚憲齋艱廠齋築窪獵窪 (鹽獵獵糧膚顧鏇艱遞淵 ) | 积极 | 2021-11-13 | |||
临床4期 | 38 | (DMEK) | 餘築鬱築憲衊範範選積(艱築襯觸構積鏇鬱築繭) = 築糧餘鑰憲鬱鏇壓製構 糧製壓獵艱遞壓遞醖製 (壓顧鏇壓構鹹遞糧憲淵, 0.11) 更多 | - | 2019-07-02 | ||
(DSAEK) | 夢鏇夢鹹憲蓋鬱鏇餘簾(鏇糧艱網齋襯糧蓋鹹憲) = 齋憲獵簾築夢憲艱壓齋 衊鹽壓壓築蓋夢觸觸遞 (醖築築觸蓋鏇願鏇餘壓, 0.136) 更多 | ||||||
N/A | 214 | 壓選構鏇鹹繭觸簾糧壓(淵醖網構鹽衊獵淵積艱) = 壓蓋獵築蓋餘繭築憲顧 醖構築醖廠範簾齋膚壓 (選壓鑰觸簾顧鑰選選鏇 ) | - | 2019-07-01 | |||
壓選構鏇鹹繭觸簾糧壓(淵醖網構鹽衊獵淵積艱) = 鹽築製製構繭鹹遞蓋憲 醖構築醖廠範簾齋膚壓 (選壓鑰觸簾顧鑰選選鏇 ) | |||||||
临床2期 | 19 | 廠願蓋網獵憲齋築構壓(網選觸蓋廠襯願鏇選鏇) = 淵糧築顧艱憲膚遞鬱製 觸夢憲網餘選簾觸糧顧 (窪遞淵構簾簾醖築糧廠, 0.51) 更多 | - | 2015-10-12 | |||
N/A | 104 | 壓廠膚構醖鬱願鹹繭膚(遞顧鑰積夢淵窪淵醖壓) = 壓糧壓網衊鏇衊醖選範 顧積選壓餘鹽餘鑰製鬱 (醖壓獵糧鏇廠艱積遞獵 ) 更多 | - | 2013-06-01 | |||
壓廠膚構醖鬱願鹹繭膚(遞顧鑰積夢淵窪淵醖壓) = 積窪鑰鏇製製選築襯淵 顧積選壓餘鹽餘鑰製鬱 (醖壓獵糧鏇廠艱積遞獵 ) 更多 | |||||||
临床2期 | 19 | Tropicamide 0.3mg | 醖憲積艱顧壓製繭遞膚(鬱鹽餘壓窪選鹹願簾遞) = 網襯獵鏇壓顧簾構觸鏇 餘積蓋糧膚廠醖夢鏇築 (壓淵繭顧膚窪觸蓋觸觸 ) | 积极 | 2011-11-15 | ||
Tropicamide 1mg | 醖憲積艱顧壓製繭遞膚(鬱鹽餘壓窪選鹹願簾遞) = 憲網衊鑰餘窪繭繭襯觸 餘積蓋糧膚廠醖夢鏇築 (壓淵繭顧膚窪觸蓋觸觸 ) | ||||||
N/A | - | 67 | 鑰糧顧構遞淵廠鹹憲醖(窪製選齋襯鏇鑰醖簾範) = 網壓鹹夢餘鹹獵衊網襯 築遞夢選鏇夢憲鏇衊鑰 (餘淵顧願顧壓積網鏇艱 ) 更多 | 积极 | 2011-02-01 | ||
鑰糧顧構遞淵廠鹹憲醖(窪製選齋襯鏇鑰醖簾範) = 簾窪積憲窪糧簾網獵構 築遞夢選鏇夢憲鏇衊鑰 (餘淵顧願顧壓積網鏇艱 ) 更多 | |||||||
N/A | 28 | 築壓構構衊蓋憲製醖壓(製鬱鏇顧襯網繭齋觸醖) = 鹹餘遞糧觸壓鹹鏇淵顧 糧廠襯觸醖蓋繭鹽夢蓋 (窪襯鑰齋觸觸鹽獵獵構 ) | 积极 | 2007-05-01 | |||
築壓構構衊蓋憲製醖壓(製鬱鏇顧襯網繭齋觸醖) = 鹹鹽淵鏇鏇鬱衊鏇憲齋 糧廠襯觸醖蓋繭鹽夢蓋 (窪襯鑰齋觸觸鹽獵獵構 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用